MX2023013582A - Regimenes de dosificacion de antagonista de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruacion. - Google Patents
Regimenes de dosificacion de antagonista de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruacion.Info
- Publication number
- MX2023013582A MX2023013582A MX2023013582A MX2023013582A MX2023013582A MX 2023013582 A MX2023013582 A MX 2023013582A MX 2023013582 A MX2023013582 A MX 2023013582A MX 2023013582 A MX2023013582 A MX 2023013582A MX 2023013582 A MX2023013582 A MX 2023013582A
- Authority
- MX
- Mexico
- Prior art keywords
- gonadotropin
- releasing hormone
- hormone antagonist
- menstruation
- dosage regimes
- Prior art date
Links
- 230000005906 menstruation Effects 0.000 title abstract 2
- 201000004458 Myoma Diseases 0.000 title 1
- 239000002474 gonadorelin antagonist Substances 0.000 title 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- -1 3-[2-fluoro-5-(2 Chemical class 0.000 abstract 1
- 239000004381 Choline salt Substances 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 235000019417 choline salt Nutrition 0.000 abstract 1
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 abstract 1
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
- KQWHKLZRDFJOCN-UHFFFAOYSA-N thieno[3,4-d]pyrimidine Chemical class N1=CN=CC2=CSC=C21 KQWHKLZRDFJOCN-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515232P | 2017-06-05 | 2017-06-05 | |
| PCT/EP2018/064767 WO2018224497A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013582A true MX2023013582A (es) | 2024-04-16 |
Family
ID=62636157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013582A MX2023013582A (es) | 2017-06-05 | 2018-06-05 | Regimenes de dosificacion de antagonista de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruacion. |
| MX2019014482A MX2019014482A (es) | 2017-06-05 | 2018-06-05 | Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014482A MX2019014482A (es) | 2017-06-05 | 2018-06-05 | Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11759464B2 (enExample) |
| EP (2) | EP4509173A3 (enExample) |
| JP (2) | JP7292566B2 (enExample) |
| KR (1) | KR102884301B1 (enExample) |
| CN (1) | CN110996957A (enExample) |
| AU (2) | AU2018280741B2 (enExample) |
| CA (1) | CA3066188A1 (enExample) |
| DK (1) | DK3634419T3 (enExample) |
| EA (1) | EA201992812A1 (enExample) |
| ES (1) | ES3018358T3 (enExample) |
| FI (1) | FI3634419T3 (enExample) |
| HR (1) | HRP20250390T1 (enExample) |
| HU (1) | HUE070907T2 (enExample) |
| MX (2) | MX2023013582A (enExample) |
| PL (1) | PL3634419T3 (enExample) |
| PT (1) | PT3634419T (enExample) |
| SG (1) | SG11201911599XA (enExample) |
| WO (1) | WO2018224497A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014143669A1 (en) | 2013-03-15 | 2014-09-18 | AbbVie Inc . | Compositions for use in treating heavy menstrual bleeding and uterine fibroids |
| US11980621B2 (en) | 2017-06-05 | 2024-05-14 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| EP4509173A3 (en) | 2017-06-05 | 2025-06-04 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| JP2021531236A (ja) | 2018-04-19 | 2021-11-18 | アッヴィ・インコーポレイテッド | 重度の月経出血を治療する方法 |
| JP2021532160A (ja) * | 2018-08-01 | 2021-11-25 | アッヴィ・インコーポレイテッド | エラゴリックスに関する投与計画 |
| MA54058A (fr) | 2018-10-29 | 2021-09-08 | ObsEva SA | Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale |
| US20230067378A1 (en) * | 2018-11-07 | 2023-03-02 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| JP2022543757A (ja) * | 2019-08-08 | 2022-10-14 | オブセヴァ エス．エー． | エストロゲン依存性障害の治療のためのｇｎｒｈアンタゴニスト |
| EP4009977A2 (en) * | 2019-08-08 | 2022-06-15 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
| KR20210155350A (ko) | 2020-06-15 | 2021-12-22 | 한상왕 | 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| KR102738115B1 (ko) | 2024-03-25 | 2024-12-05 | 한상왕 | 자궁근종 예방, 개선 또는 치료용 약학 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7109171B2 (en) | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| RU2418803C2 (ru) * | 2005-10-19 | 2011-05-20 | Киссеи Фармасьютикал Ко., Лтд. | Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине |
| CA2788533C (en) * | 2010-02-10 | 2018-03-06 | Kissei Pharmaceutical Co., Ltd. | Choline salt of fused heterocyclic derivative and pharmaceutical composition containing the same |
| WO2014042176A1 (ja) | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| WO2014143669A1 (en) | 2013-03-15 | 2014-09-18 | AbbVie Inc . | Compositions for use in treating heavy menstrual bleeding and uterine fibroids |
| BR112019002513A2 (pt) | 2016-08-08 | 2019-05-14 | Kissei Pharmaceutical Co., Ltd. | uso e dosagem de agentes terapêuticos para endometriose |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| US11980621B2 (en) | 2017-06-05 | 2024-05-14 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| EP4509173A3 (en) | 2017-06-05 | 2025-06-04 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| US20230067378A1 (en) | 2018-11-07 | 2023-03-02 | ObsEva S.A. | Compositions and methods for the treatment of estrogen-dependent disorders |
-
2018
- 2018-06-05 EP EP24221894.9A patent/EP4509173A3/en active Pending
- 2018-06-05 CN CN201880050807.2A patent/CN110996957A/zh active Pending
- 2018-06-05 PT PT187319769T patent/PT3634419T/pt unknown
- 2018-06-05 AU AU2018280741A patent/AU2018280741B2/en active Active
- 2018-06-05 MX MX2023013582A patent/MX2023013582A/es unknown
- 2018-06-05 WO PCT/EP2018/064767 patent/WO2018224497A1/en not_active Ceased
- 2018-06-05 EP EP18731976.9A patent/EP3634419B1/en active Active
- 2018-06-05 JP JP2019566909A patent/JP7292566B2/ja active Active
- 2018-06-05 DK DK18731976.9T patent/DK3634419T3/da active
- 2018-06-05 ES ES18731976T patent/ES3018358T3/es active Active
- 2018-06-05 MX MX2019014482A patent/MX2019014482A/es unknown
- 2018-06-05 PL PL18731976.9T patent/PL3634419T3/pl unknown
- 2018-06-05 FI FIEP18731976.9T patent/FI3634419T3/fi active
- 2018-06-05 SG SG11201911599XA patent/SG11201911599XA/en unknown
- 2018-06-05 CA CA3066188A patent/CA3066188A1/en active Pending
- 2018-06-05 US US16/619,702 patent/US11759464B2/en active Active
- 2018-06-05 HU HUE18731976A patent/HUE070907T2/hu unknown
- 2018-06-05 HR HRP20250390TT patent/HRP20250390T1/hr unknown
- 2018-06-05 KR KR1020197038980A patent/KR102884301B1/ko active Active
- 2018-06-05 EA EA201992812A patent/EA201992812A1/ru unknown
-
2023
- 2023-03-20 JP JP2023043718A patent/JP7485815B2/ja active Active
- 2023-09-11 US US18/244,773 patent/US20240000785A1/en active Pending
-
2024
- 2024-03-14 AU AU2024201694A patent/AU2024201694A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3634419A1 (en) | 2020-04-15 |
| AU2024201694A1 (en) | 2024-04-04 |
| JP2020522525A (ja) | 2020-07-30 |
| JP2023078315A (ja) | 2023-06-06 |
| EP4509173A3 (en) | 2025-06-04 |
| EP3634419B1 (en) | 2025-01-29 |
| US20200179390A1 (en) | 2020-06-11 |
| AU2018280741A1 (en) | 2020-01-30 |
| JP7292566B2 (ja) | 2023-06-19 |
| KR102884301B1 (ko) | 2025-11-11 |
| HUE070907T2 (hu) | 2025-07-28 |
| JP7485815B2 (ja) | 2024-05-16 |
| US11759464B2 (en) | 2023-09-19 |
| PT3634419T (pt) | 2025-04-04 |
| EA201992812A1 (ru) | 2020-05-21 |
| DK3634419T3 (da) | 2025-03-31 |
| PL3634419T3 (pl) | 2025-06-09 |
| US20240000785A1 (en) | 2024-01-04 |
| MX2019014482A (es) | 2020-08-17 |
| EP4509173A2 (en) | 2025-02-19 |
| SG11201911599XA (en) | 2020-01-30 |
| HRP20250390T1 (hr) | 2025-05-23 |
| AU2018280741B2 (en) | 2023-12-21 |
| WO2018224497A1 (en) | 2018-12-13 |
| CN110996957A (zh) | 2020-04-10 |
| KR20200024797A (ko) | 2020-03-09 |
| FI3634419T3 (fi) | 2025-05-02 |
| ES3018358T3 (es) | 2025-05-16 |
| CA3066188A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992812A1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери | |
| MX2021013139A (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| MX2016007111A (es) | Inhibidores de tirosina quinasa de bruton. | |
| SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| PE20191710A1 (es) | Modulador del receptor de androgeno y usos de este | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| BR112015020302A2 (pt) | derivado de pirazol | |
| UY35391A (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c | |
| EA201590847A1 (ru) | Новые ингибиторы rock | |
| PH12014502516B1 (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| MX2015015500A (es) | Composiciones de cenicriviroc y metodos para elaborarlas y usarlas. | |
| WO2020094698A3 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| PH12019501016A1 (en) | Treatment of cns diseases with sgc stimulators | |
| BR112015029353A2 (pt) | derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| BR112017028048A2 (pt) | drospirenona como o único ingrediente contraceptivo para uso | |
| MX376312B (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash | |
| MX347927B (es) | Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb. | |
| CL2019000018A1 (es) | Formas sólidas de un estimulador de sgc. | |
| AR116021A1 (es) | Composición farmacéutica que comprende clopidogrel y tegoprazan y uso de los mismos para prepararla | |
| BR112016023450A2 (pt) | uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce | |
| CU20160044A7 (es) | DERIVADOS DE 2,4 DIOXO-1,2,3,4-TETRAHIDROTIENO(2,3-d) PIRIMIDINA-6-CARBOXAMIDAS COMO ANTAGONISTAS DE RECEPTORES A2b DE ADENOSINA | |
| MX388825B (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| GT201400153A (es) | Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina | |
| BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida |